Literature DB >> 14305970

A METHYLHYDRAZINE DERIVATIVE IN HODGKIN'S DISEASE AND OTHER MALIGNANT NEOPLASMS. THERAPEUTIC AND TOXIC EFFECTS STUDIED IN 51 PATIENTS.

K W BRUNNER, C W YOUNG.   

Abstract

Entities:  

Keywords:  ALKYLATING AGENTS; ANTINEOPLASTIC AGENTS; BONE MARROW; BRAIN; DRUG THERAPY; HODGKIN'S DISEASE; HYDRAZINES; LEUKOPENIA; LIVER; LUNG; NEOPLASM THERAPY; PATHOLOGY; PHARMACOLOGY; THORACIC RADIOGRAPHY; THROMBOPENIA; TOXICOLOGIC REPORT; VINBLASTINE

Mesh：

Substances：

Year:  1965        PMID： 14305970     DOI： 10.7326/0003-4819-63-1-69

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  6 in total

1.  C-MOPP: the forgotten regimen plus Rituximab for untreated and relapsed follicular lymphoma.

Authors:  Mark J Fesler; Medhat Osman; James Glauber; Paul J Petruska
Journal:  Am J Blood Res       Date:  2011-09-22

2.  [Long term treatment of advanced vinblastine-resistant lymphogranulomatosis with ibenzmethyzin (Natulan)].

Authors:  E Schulz; H Cissée; K Hausmann
Journal:  Klin Wochenschr       Date:  1970-11-01

Review 3.  Hypersensitivity reactions from antineoplastic agents.

Authors:  R B Weiss; J R Baker
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 4.  Prevention and management of drug-induced peripheral neuropathy.

Authors:  L L Olesen; T S Jensen
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

5.  Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors.

Authors:  Jean-Pierre Armand; Vincent Ribrag; Jean-Luc Harrousseau; Lauren Abrey
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

6.  Assessment of the evolution of cancer treatment therapies.

Authors:  Manuel Arruebo; Nuria Vilaboa; Berta Sáez-Gutierrez; Julio Lambea; Alejandro Tres; Mónica Valladares; Africa González-Fernández
Journal:  Cancers (Basel)       Date:  2011-08-12       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.